Project Updates and Milestones news (page 19)

13 April 2026

Genmab: Rina‑S plus bevacizumab tolerable in advanced ovarian cancer

RAINFOL‑01 D2 (n=40): common TEAEs—nausea 80%, fatigue 67.5%, anemia 55%, neutropenia 45%; serious TEAEs 15%; dose reductions 27.5%; no fatal TEAEs. Phase 3 RAINFOL‑04 ongoing.
13 April 2026

Daiichi Sankyo and Merck: FDA Priority Review for Ifinatamab Deruxtecan in ES‑SCLC

BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).
13 April 2026

Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026

12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins
13 April 2026

Lilly: Jaypirca plus venetoclax‑rituximab extends PFS in previously treated CLL/SLL

Phase 3 BRUIN CLL-322 (n=639) in relapsed/refractory CLL/SLL: time-limited (2-yr) pirtobrutinib with venetoclax+rituximab showed consistent benefit across subgroups; safety similar; OS immature.
13 April 2026

Petrobras discovers hydrocarbons in deepwater pre‑salt Campos Basin well

Hydrocarbons found in pre-salt of Campos Basin (block C‑M‑477) in exploratory well 201 km off Rio de Janeiro at 2,984 m water depth; presence confirmed by logs, gas shows and fluid samples.
13 April 2026

QatarEnergy finds hydrocarbons offshore Republic of Congo

Discovery in MHNM-6 NFW well on Moho G offshore Congo: 160m hydrocarbon column in good-quality Albian reservoirs; data and samples collected for subsurface interpretation.

The right choices in the European chemical industry

Save time with chemXplore Alpha

Learn more

← Previous Next →